BOULDER, Colo. — VitriVax, Inc., a vaccine formulation technology company, announced it has raised $17.25 million in Series B financing to advance development and commercialization of its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) platform. The round was co-led by Adjuvant Capital and RA Capital Management.
“The completion of our Series B financing marks an important milestone for VitriVax as we continue to advance the development of ALTA, our thermostable, single-shot vaccine platform,” said Romulo Colindres, Chief Executive Officer of VitriVax. “This funding positions us well to execute on our regulatory and clinical strategies, bringing us closer to addressing critical needs in vaccine access and immunization coverage.”
VitriVax’s ALTA technology is designed to eliminate the need for cold-chain storage and enable single-dose vaccine formulations, simplifying immunization logistics and reducing costs. By stabilizing vaccines at ambient temperatures, the platform has the potential to improve access to lifesaving immunizations, particularly in low-resource or remote regions.
“We are pleased to support VitriVax as they work to address critical challenges in vaccine development and delivery,” said Glenn Rockman, Founder and Managing Partner at Adjuvant Capital. “Thermostable, single-administration products have the potential to shift the paradigm in how vaccines are distributed and administered, potentially accelerating many long-sought public health goals.”
The financing follows a $9.9 million grant from the Bill & Melinda Gates Foundation to support aseptic manufacturing and GMP readiness for Phase 1 clinical trials. VitriVax has also received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and a multi-year contract from the U.S. Department of Defense, further supporting the advancement of the ALTA platform toward first-in-human testing.
